TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1785235

Group type: EXPERIMENTAL
Intervention: Unlimited access to oral water until 2 hours before anaesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 7131548

Group type: EXPERIMENTAL
Intervention: Nicotine gum (2 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nicotine gum (2 mg) for high-nicotine-dependent smokers
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo chewing gum for high-nicotine-dependent smokers
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nicotine gum (2 mg) for low-nicotine-dependent smokers
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo chewing gum for low-nicotine-dependent smokers
Number of subjects: 100
Study: 31355447

Group type: EXPERIMENTAL
Intervention: Ridge preservation using freeze-dried bone allograft (FDBA)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Nonresorbable dense polytetrafluoroethylene (dPTFE) membrane
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Absorbable collagen sponge
Number of subjects: 79

Group type: COMPARATOR
Intervention: Extraction alone (control)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Ridge preservation using FDBA
Number of subjects: 79
Study: 29421829

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) intervention, 8 sessions
Number of subjects: 113

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 113
Study: 27379953

Group type: COMPARATOR
Intervention: 0% maltodextrin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 3% maltodextrin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 6% maltodextrin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 12% maltodextrin
Number of subjects: 15
Study: 25647781

Group type: EXPERIMENTAL
Intervention: Axitinib/gemcitabine
Number of subjects: 632

Group type: COMPARATOR
Intervention: Placebo/gemcitabine
Number of subjects: 632
Study: 25035126

Group type: COMPARATOR
Intervention: Self-moulded MAD (SleepPro 1; SP1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Semi-bespoke MAD (SleepPro 2; SP2)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Fully-bespoke MAD (bMAD)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: No treatment
Number of subjects: 90
Study: 22865999

Group type: EXPERIMENTAL
Intervention: Cognitive-motor exercise program (twice weekly for 12 weeks) including strength and balance training and dance video gaming
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention)
Number of subjects: 0
Study: 20021688

Group type: EXPERIMENTAL
Intervention: Videotape recording and verbal feedback
Number of subjects: 52

Group type: COMPARATOR
Intervention: Verbal feedback alone
Number of subjects: 52
Study: 17479539

Group type: EXPERIMENTAL
Intervention: New retard tablet formulation of verapamil (240 mg oral dose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard retard tablet formulation of verapamil (240 mg oral dose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) dose of verapamil (5 mg)
Number of subjects: 12
Study: 15045502

Group type: EXPERIMENTAL
Intervention: Voluntary exercise (leg extension‐flexion movement for 20 s with weights corresponding to 5% of body mass)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Passive movement (experimenter pulling ropes connected to subjects' ankles for 20 s)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Passive movement
Number of subjects: 22

Group type: COMPARATOR
Intervention: Voluntary exercise
Number of subjects: 22
Study: 12126596

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 980

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 980
Study: 9113177

Group type: EXPERIMENTAL
Intervention: 0.125 mg/kg morphine in 60 ml saline administered intravenously into the exsanguinated operative limb
Number of subjects: 50

Group type: COMPARATOR
Intervention: 60 ml saline administered intravenously into the operative leg and 0.125 mg/kg morphine intramuscularly into the opposite leg
Number of subjects: 50
Study: 1586526

Group type: EXPERIMENTAL
Intervention: Haemoccult test kit posted without health check invitation
Number of subjects: 1588

Group type: EXPERIMENTAL
Intervention: Haemoccult test kit posted with health check invitation
Number of subjects: 1588

Group type: EXPERIMENTAL
Intervention: Health check invitation posted with Haemoccult test kit offered at health check
Number of subjects: 1588

Group type: COMPARATOR
Intervention: Health check invitation posted without Haemoccult test kit
Number of subjects: 1588

Group type: EXPERIMENTAL
Intervention: Haemoccult test kit enclosed with health check invitation
Number of subjects: 1588

Group type: EXPERIMENTAL
Intervention: Haemoccult test kit offered at health check
Number of subjects: 1588
Study: 2580181

Group type: EXPERIMENTAL
Intervention: Captopril plus a thiazide diuretic (37.5-75 mg/day)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Propranolol plus a diuretic (60-120 mg/day)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Captopril plus a thiazide diuretic
Number of subjects: 270

Group type: COMPARATOR
Intervention: Propranolol plus a diuretic
Number of subjects: 270
Study: 29373148

Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 74
Study: 29305130

Group type: EXPERIMENTAL
Intervention: Mediterranean diet intervention
Number of subjects: 7170

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 7170

Group type: EXPERIMENTAL
Intervention: Vegetable intake (part of Mediterranean diet)
Number of subjects: 7170
Study: 26599222

Group type: EXPERIMENTAL
Intervention: Potassium supplementation (2.8 g/day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 24604348

Group type: EXPERIMENTAL
Intervention: Contact lenses
Number of subjects: 114

Group type: COMPARATOR
Intervention: Intraocular lenses (IOL)
Number of subjects: 114
Study: 21798763

Group type: EXPERIMENTAL
Intervention: A‐CASI screening and referral
Number of subjects: 126

Group type: COMPARATOR
Intervention: HCP screening and referral
Number of subjects: 126

Group type: COMPARATOR
Intervention: A‐CASI referral with HCP endorsement
Number of subjects: 126

Group type: COMPARATOR
Intervention: A‐CASI alone
Number of subjects: 126
Study: 20410835

Group type: EXPERIMENTAL
Intervention: In-treatment EFS
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: In-treatment stress-corrected EFS
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: In-treatment MWS
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: In-treatment stress-corrected MWS
Number of subjects: 840
Study: 18656314

Group type: EXPERIMENTAL
Intervention: Daily smokers
Number of subjects: 72

Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Chippers
Number of subjects: 72
Study: 15943950

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone treatment in a Primary Care Clinic (PCC) for 26 weeks
Number of subjects: 96

Group type: COMPARATOR
Intervention: Methadone maintenance treatment in an Opioid Treatment Program (OTP)
Number of subjects: 96
Study: 11814492

Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol 30 microg plus norgestrel 300 microg starting on menstrual cycle day 1
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol 30 microg plus norgestrel 300 microg starting on menstrual cycle day 4
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol 30 microg plus norgestrel 300 microg starting on menstrual cycle day 7
Number of subjects: 130

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 130
Study: 10530860

Group type: EXPERIMENTAL
Intervention: Reconstructed ACL using autogenous semitendinosus and gracilis tendons
Number of subjects: 32

Group type: COMPARATOR
Intervention: Injured ACL
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal ACL
Number of subjects: 32
Study: 7489471

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 29

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 29
Study: 1987818

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study: 6366133

Group type: EXPERIMENTAL
Intervention: CMFVP (Cyclophosphamide, Methotrexate, 5-Fluorouracil + Vincristine + Prednisone)
Number of subjects: 401

Group type: COMPARATOR
Intervention: CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: CMF-MER (Cyclophosphamide, Methotrexate, 5-Fluorouracil + Methanol Extraction Residue of BCG)
Number of subjects: 401

Group type: COMPARATOR
Intervention: CMF
Number of subjects: 401
Study: 31479105

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg twice daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: Dose-adjusted warfarin
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 120

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 120
Study: 29685792

Group type: EXPERIMENTAL
Intervention: Vitamin D3 4000 IU daily for 12 months
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Vitamin D3 2000 IU daily for 12 months
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study: 27737356

Group type: EXPERIMENTAL
Intervention: Mandibular overdentures supported by two implants with bar‐clip system and a maxillary conventional denture (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: New maxillary and mandibular conventional complete dentures (n = 25)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mandibular overdentures supported by two implants with bar‐clip system
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional dentures
Number of subjects: 50
Study: 24768939

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (physical exercise, nutrition, cognitive training)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 22664690

Group type: EXPERIMENTAL
Intervention: Listening to music
Number of subjects: 69

Group type: COMPARATOR
Intervention: No music (Control)
Number of subjects: 69
Study: 19562361

Group type: EXPERIMENTAL
Intervention: Dictation of the letter to the GP in front of the patient
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-dictation of the letter to the GP
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-dictation group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dictation group
Number of subjects: 100
Study: 17685675

Group type: EXPERIMENTAL
Intervention: Pushing the motor vehicle (MV)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pulling the motor vehicle (MV)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pushing and pulling the MV
Number of subjects: 6
Study: 15772563

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Raloxifene 150 mg/d
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen 0.625 mg/d
Number of subjects: 619

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 619
Study: 12130970

Group type: EXPERIMENTAL
Intervention: H2-blockers
Number of subjects: 0
Study: 9695541

Group type: EXPERIMENTAL
Intervention: Spontaneous occurrence of Pulfrich's stereophenomenon in retrobulbar neuritis patients
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Spontaneous occurrence of Pulfrich's stereophenomenon in demyelinating patients
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Pulfrich's pendulum test in demyelinating patients
Number of subjects: 49
Study: 8082084

Group type: EXPERIMENTAL
Intervention: Younger than 2 years of age at diagnosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tumors weighing less than 550 g
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tumors weighing more than 550 g
Number of subjects: 0
Study: 2692062

Group type: EXPERIMENTAL
Intervention: Study group patients
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group patients
Number of subjects: 85
Study: 4916196

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulphamethoxazole
Number of subjects: 220

Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 220
Study: 31843839

Group type: EXPERIMENTAL
Intervention: Multi‐component in‐hospital intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control hospitals
Number of subjects: 20
Study: 28133947

Group type: EXPERIMENTAL
Intervention: Gaming Group (GG)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 44
Study: 24849000

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate (CG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Povidone iodine (PI)
Number of subjects: 60
Study: 22595983

Group type: EXPERIMENTAL
Intervention: Room air
Number of subjects: 16

Group type: COMPARATOR
Intervention: 50% supplemental O2
Number of subjects: 16
Study: 20537177

Group type: EXPERIMENTAL
Intervention: Network meta-analysis combining count and hazard ratio statistics
Number of subjects: 0
Study: 18566295

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/d)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/d)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Atorvastatin and Fenofibrate
Number of subjects: 11
Study: 16038387

Group type: EXPERIMENTAL
Intervention: Dynamic bubble trap (DBT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No dynamic bubble trap (DBT)
Number of subjects: 12
Study: 12501880

Group type: EXPERIMENTAL
Intervention: Once-weekly alendronate 70 mg
Number of subjects: 288

Group type: COMPARATOR
Intervention: Once-daily alendronate 10 mg
Number of subjects: 288
Study: 10366909

Group type: EXPERIMENTAL
Intervention: 1 week postoperative immobilization
Number of subjects: 60

Group type: COMPARATOR
Intervention: 6 weeks postoperative immobilization
Number of subjects: 60
Study: 7673615

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg/day for 8 weeks (GU) or 6 weeks (DU)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Dual therapy of lansoprazole 30 mg/day and amoxicillin (AMPC) 1 g/day or clarithromycin (CAM) 400 mg/day for 2 weeks
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Combination therapy of lansoprazole 30 mg/day, AMPC 1 g/day, or CAM 400 mg/day, and metronidazole 500 mg/day for 2 weeks
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 88
Study: 2210280

Group type: EXPERIMENTAL
Intervention: Disposable plastic biopsy forceps
Number of subjects: 30

Group type: COMPARATOR
Intervention: Reusable stainless steel forceps
Number of subjects: 30
Study: 7032411

Group type: EXPERIMENTAL
Intervention: Metronidazole (single intravenous dose)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control (no metronidazole)
Number of subjects: 203
Study: 29898141

Group type: EXPERIMENTAL
Intervention: N‐acetylcysteine, vitamin C and selenium (600 mg, 1500 mg, 0.5 mg respectively) administered orally twice a day from the day before to 2 days after surgery
Number of subjects: 291

Group type: COMPARATOR
Intervention: Control group (nothing administered)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: All groups (N‐acetylcysteine, vitamin C, selenium, and control)
Number of subjects: 291
Study: 27227933

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (9 mL/kg bicarbonate 154 mmol/L)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Saline (0.9%)
Number of subjects: 152
Study: 24703574

Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m² with vitamin B12 and folic acid q3w
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m² with vitamin B12 and folic acid q3w + Erlotinib 150 mg daily
Number of subjects: 159
Study: 22386118

Group type: EXPERIMENTAL
Intervention: Tools for Getting Along (TFGA) curriculum
Number of subjects: 1296
Study: 20544227

Group type: EXPERIMENTAL
Intervention: Radio Frequency (RF)
Number of subjects: 2

Group type: COMPARATOR
Intervention: High-Intensity Focused Ultrasound (HIFU)
Number of subjects: 2
Study: 18235116

Group type: EXPERIMENTAL
Intervention: Imatinib (100 to 800 mg daily)
Number of subjects: 60
Study: 15881476

Group type: EXPERIMENTAL
Intervention: clarithromycin ER 1000 mg once daily
Number of subjects: 437
Study: 12877665

Group type: EXPERIMENTAL
Intervention: Epoetin beta 30,000 IU subcutaneously once weekly (q.w.)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Epoetin beta 10,000 IU three-times weekly (t.i.w.)
Number of subjects: 241
Study: 10490792

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET) for 4 months, 5 days/week, 40 minutes/day
Number of subjects: 79

Group type: COMPARATOR
Intervention: Cessation of Exercise Training (no-ET) for 4 months after 4 months of ET
Number of subjects: 79
Study: 7503620

Group type: EXPERIMENTAL
Intervention: verapamil 480 mg/day
Number of subjects: 809

Group type: COMPARATOR
Intervention: metoprolol 200 mg/day
Number of subjects: 809
Study: 1782922

Group type: EXPERIMENTAL
Intervention: Oral zinc sulphate 185.4 mg per day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 6890407

Group type: EXPERIMENTAL
Intervention: Scopolamine delivered by transdermal patch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31917748

Group type: EXPERIMENTAL
Intervention: Self-report of viral suppression
Number of subjects: 0
Study: 30565793

Group type: EXPERIMENTAL
Intervention: Donepezil (10 mg/daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28222555

Group type: EXPERIMENTAL
Intervention: Scapulohumeral rehabilitation protocol (20 minutes per day, 5 days a week, for 6 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional arm rehabilitation (control group)
Number of subjects: 28
Study: 26094050

Group type: EXPERIMENTAL
Intervention: Indacaterol
Number of subjects: 1422

Group type: COMPARATOR
Intervention: Tiotropium
Number of subjects: 1422
Study: 24608196

Group type: EXPERIMENTAL
Intervention: NEPA100 + PALO 0.50 mg
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: NEPA200 + PALO 0.50 mg
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: NEPA300 + PALO 0.50 mg
Number of subjects: 694

Group type: COMPARATOR
Intervention: PALO 0.50 mg
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: APR + OND 32 mg
Number of subjects: 694
Study: 22554092

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 152
Study: 19605373

Group type: EXPERIMENTAL
Intervention: Supervised aquatic training (3 weekly sessions of 60 min for 32 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Supervised aquatic training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 17240136

Group type: EXPERIMENTAL
Intervention: IM‐MS irradiation
Number of subjects: 4004

Group type: COMPARATOR
Intervention: No IM‐MS irradiation
Number of subjects: 4004
Study: 15751168

Group type: EXPERIMENTAL
Intervention: Dalteparin (5000 IU, daily subcutaneous injections for 14 days)
Number of subjects: 3681

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3681
Study: 11788639

Group type: EXPERIMENTAL
Intervention: High-dose GH (100 mcg/kg/day)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Post-GH treatment
Number of subjects: 13

Group type: COMPARATOR
Intervention: Non-GH treated children
Number of subjects: 13
Study: 10517552

Group type: EXPERIMENTAL
Intervention: Intravenous morphine (MOR) administration
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (MOR) administration
Number of subjects: 9
Study: 7593423

Group type: EXPERIMENTAL
Intervention: GHRH (1 microgram/kg, iv)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: GHRP-6 (1 microgram/kg, iv)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: GHRH plus GHRP-6
Number of subjects: 14
Study: 2108196

Group type: EXPERIMENTAL
Intervention: hCG (1500 IU every 6 days)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: hCG (1500 IU every 6 days) + FSH (75 IU every 3 days)
Number of subjects: 10
Study: 109598

Group type: EXPERIMENTAL
Intervention: Test regimen of prednisone therapy (higher dosage, longer duration)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard prednisone relapse regimen
Number of subjects: 54
Study: 31710930

Group type: EXPERIMENTAL
Intervention: Maternal Pregnancy-Related Anxiety Questionnaire (PRAQ-R2) scores at gestational week 24
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Maternal Pregnancy-Related Anxiety Questionnaire (PRAQ-R2) scores at gestational week 34
Number of subjects: 19
Study: 31054292

Group type: EXPERIMENTAL
Intervention: Tokuyama Bond Force II™ adhesive system (Group 5)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Gluma Self Etch™ adhesive system (Group 1)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Non‐roughened and non‐conditioned surfaces (Group 3)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Sandblasting and Gluma Self Etch™ (Group 4)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Sandblasting only (Group 6)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Positive control group
Number of subjects: 105
Study: 28673323

Group type: EXPERIMENTAL
Intervention: Bracelet- and self-directed observational therapy (BSDOT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 26519114

Group type: EXPERIMENTAL
Intervention: Aldosterone antagonist (spironolactone) in combination with RAAS blockers
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (RAAS blockers only)
Number of subjects: 71
Study: 23587902

Group type: EXPERIMENTAL
Intervention: Sinogram affirmed iterative reconstruction (SAFIRE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Filtered back projection (FBP)
Number of subjects: 30
Study: 21170603

Group type: EXPERIMENTAL
Intervention: Cr brewer's yeast supplementation (500 μg Cr/person/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 19224907

Group type: EXPERIMENTAL
Intervention: Preoperative quadriceps strength
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Preoperative quadriceps strength deficits above 20%
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Meniscus injury
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Short‐Form‐36 Bodily Pain sub score
Number of subjects: 73
Study: 17200492

Group type: EXPERIMENTAL
Intervention: 25 mg/day of zonisamide (ZNS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50 mg/day of zonisamide (ZNS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100 mg/day of zonisamide (ZNS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0